These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 7841089)

  • 21. Left ventricular hypertrophy: impact of calcium channel blocker therapy.
    Messerli FH
    Am J Med; 1991 May; 90(5A):27S-31S. PubMed ID: 2039017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
    Wachtell K; Palmieri V; Gerdts E; Bella JN; Aurigemma GP; Papademetriou V; Dahlöf B; Aalto T; Ibsen H; Rokkedal JE; Devereux RB
    Am J Cardiol; 2010 Oct; 106(7):999-1005. PubMed ID: 20854964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K; Okin PM; Olsen MH; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Nieminen MS; Thygesen K
    Circulation; 2007 Aug; 116(7):700-5. PubMed ID: 17664372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension.
    Messerli FH; Schmieder R
    Drugs; 1986; 31 Suppl 4():192-201. PubMed ID: 2942387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension, left ventricular hypertrophy, ventricular ectopy, and sudden death.
    Messerli FH
    Am J Hypertens; 1993 Apr; 6(4):335-6. PubMed ID: 7685177
    [No Abstract]   [Full Text] [Related]  

  • 27. Left ventricular hypertrophy: should it be reduced?
    Messerli FH; Soria F; Aristizabal D
    Clin Cardiol; 1993 May; 16(5 Suppl 2):II15-20. PubMed ID: 8504585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Impact of arterial hypertension on the heart].
    Herpin D
    Rev Prat; 1999 Mar; 49(5):491-4. PubMed ID: 10358398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?
    Frohlich ED
    J Am Coll Cardiol; 2004 Jun; 43(12):2216-8. PubMed ID: 15193682
    [No Abstract]   [Full Text] [Related]  

  • 30. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy.
    Schmieder RE; Messerli FH
    Am Heart J; 1992 Jan; 123(1):89-95. PubMed ID: 1530898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence favoring the hypothesis that ventricular arrhythmias have prognostic significance in left ventricular hypertrophy secondary to systemic hypertension.
    Almendral J; Villacastin JP; Arenal A; Tercedor L; Merino JL; Delcan JL
    Am J Cardiol; 1995 Nov; 76(13):60D-63D. PubMed ID: 7495220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wall stress and hypertension.
    James MA; Saadeh AM; Jones JV
    J Cardiovasc Risk; 2000 Jun; 7(3):187-90. PubMed ID: 11006887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salt sensitivity and left ventricular hypertrophy.
    Coca A; De la Sierra A
    Adv Exp Med Biol; 1997; 432():91-101. PubMed ID: 9433515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Morphologic left ventricular patterns and prevalence of high-grade ventricular arrhythmias in the normotensive and hypertensive elderly.
    Mammarella A; Paradiso M; Basili S; De Matteis A; Cardarello CM; Di Franco M; Donnarumma L; Labbadia G; Paoletti V
    Adv Ther; 2000; 17(5):222-9. PubMed ID: 11186142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical impact of left ventricular hypertrophy and implications for regression.
    Artham SM; Lavie CJ; Milani RV; Patel DA; Verma A; Ventura HO
    Prog Cardiovasc Dis; 2009; 52(2):153-67. PubMed ID: 19732607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertension and left-ventricular hypertrophy.
    Messerli FH; Aepfelbacher FC
    Cardiol Clin; 1995 Nov; 13(4):549-57. PubMed ID: 8565018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Oikarinen L; Nieminen MS; Viitasalo M; Toivonen L; Jern S; Dahlöf B; Devereux RB; Okin PM;
    Hypertension; 2004 May; 43(5):1029-34. PubMed ID: 15037560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hypertensive cardiopathy and arrhythmias].
    López Gil M; Arribas F; Velázquez MT; Casas P
    Rev Esp Cardiol; 1997; 50 Suppl 4():68-73. PubMed ID: 9411591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).
    Malmqvist K; Kahan T; Edner M; Bergfeldt L
    Am J Cardiol; 2002 Nov; 90(10):1107-12. PubMed ID: 12423712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sudden cardiac death in patients with arterial hypertension and left ventricular hypertrophy on antihypertensive therapy].
    Lietava J; Dúbrava M
    Bratisl Lek Listy; 1997; 98(7-8):390-5. PubMed ID: 9471332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.